Overview

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn the effectiveness of sorafenib combined with gemcitabine plus cisplatin in the treatment of patients with locally advanced or metastatic collecting duct carcinoma(CDC) of the kidney. The safety of each treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital
Collaborator:
Bayer
Treatments:
Cisplatin
Gemcitabine
Niacinamide
Sorafenib